<i>In Vitro</i> Inhibition of CYP2C9-Mediated Warfarin 7-Hydroxylation by Iguratimod-Reference-Cited by-同舟云学术

In Vitro Inhibition of CYP2C9-Mediated Warfarin 7-Hydroxylation by Iguratimod

Published:2015 Issue:3 Volume:38 Page:441-447
ISSN:0918-6158
Container-title:Biological & Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Yamaori Satoshi¹²,Takami Ken³,Shiozawa Ayaka¹²,Sakuyama Kanako¹,Matsuzawa Naoki¹,Ohmori Shigeru¹²

Affiliation:

1. Department of Pharmacy, Shinshu University Hospital

2. Department of Biochemical Pharmacology and Toxicology, Graduate School of Medicine, Shinshu University

3. School of Medicine, Shinshu University

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/38/3/38_b14-00711/_pdf

Reference20 articles.

1. 1) Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Hara M, Iguratimod-Clinical Study Group. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod. Rheumatol., 23, 430–439 (2013).

2. 2) Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K, Iguratimod-Clinical Study Group. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod. Rheumatol., 24, 410–418 (2014).

3. 3) Taisho Toyama Pharmaceutical Co., Ltd., Japan. Interview Form (KOLBET® Tablets 25 mg), 6th edition (2013).

4. 4) Ministry of Health, Labour, and Welfare, Japan. “Careram® Tablets 25mg; KOLBET® Tablets 25mg (Iguratimod)-Risk of severe haemorrhages by a suspected interaction with warfarin.”: ‹http://www.pmda.go.jp/english/service/pdf/letter/130517-iguratimod.pdf›, cited 25 September, 2014.

5. 5) O’Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin. Pharmacol. Ther., 16, 348–354 (1974).

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study on the Effect of Three CYP2C9 Variants on Drug–Drug Interaction Related to Six Drugs In Vitro by LC–MS/MS Method;Chromatographia;2022-01-06

2. Proposal of a prediction model describing the metabolic interaction between warfarin and sorafenib using a population pharmacokinetic approach;Int. Journal of Clinical Pharmacology and Therapeutics;2021-03-01

3. Effects of acid and lactone forms of statins on S-warfarin 7-hydroxylation catalyzed by human liver microsomes and recombinant CYP2C9 variants (CYP2C9.1 and CYP2C9.3);Drug Metabolism and Pharmacokinetics;2021-02

4. Efficacy and safety of iguratimod combined with methotrexate vs. methotrexate alone in rheumatoid arthritis;Zeitschrift für Rheumatologie;2020-12-21

5. Prediction of the impact of CYP2C9 and VKORC1 genotypes on warfarin–sorafenib interactions in whites and Asians;Pharmacogenomics;2020-08